e-learning
resources
ERJ
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Changes in respiratory symptoms during 48-week treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies
James D. Chalmers, David Cipolla, Bruce Thompson, Angela M. Davis, Anne O'Donnell, Gregory Tino, Igor Gonda, Charles Haworth, Juergen Froehlich
Source:
Eur Respir J, 56 (4) 2000110; 10.1183/13993003.00110-2020
Journal Issue:
October
Disease area:
Airway diseases, Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
James D. Chalmers, David Cipolla, Bruce Thompson, Angela M. Davis, Anne O'Donnell, Gregory Tino, Igor Gonda, Charles Haworth, Juergen Froehlich. Changes in respiratory symptoms during 48-week treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies. Eur Respir J, 56 (4) 2000110; 10.1183/13993003.00110-2020
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Related content which might interest you:
Late Breaking Abstract - Changes in respiratory symptoms during 48 weeks treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies
Source: Virtual Congress 2020 – ALERT: Infection in adults and children
Year: 2020
A placebo-controlled study of liposomal amikacin for inhalation nebulized once daily in the treatment of bronchiectasis patients with chronic
pseudomonas aeruginosa
lung infection
Source: Annual Congress 2009 - Respiratory infection caused by Pseudomonas aeruginosa
Year: 2009
Short and long-term outcomes of moxifloxacin (MXF) compared to standard antibiotic treatment (STD) in acute exacerbations of chronic bronchitis (AECB): The MOSAIC study
Source: Eur Respir J 2003; 22: Suppl. 45, 566s
Year: 2003
Amoxicillin-clavulanate versus azithromycin for respiratory exacerbations in children with bronchiectasis: the BEST-2 trial
Source: International Congress 2018 – Bronchiectasis: new insights in diagnosis and treatment
Year: 2018
Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results
Source: Eur Respir J 2009; 34: 641
Year: 2009
Short-term efficacy of moxifloxacin (MXF) compared to standard antibiotic treatment (STD) in acute exacerbations of chronic bronchitis (AECB): A multivariate analysis from the MOSAIC study
Source: Eur Respir J 2003; 22: Suppl. 45, 351s
Year: 2003
Treatment effect of inhaled prolonged bronchodilator therapy (IPBT) combined with inhaled glucocorticosteroids (IGCS) on respiratory symptoms and external respiratory function in MDR pulmonary TB patients with broncho-obstructive syndrome (BOS)
Source: Annual Congress 2012 - New insights in the clinical management of lung diseases
Year: 2012
LATE-BREAKING ABSTRACT: A dose-ranging study of dupilumab in patients (pts) with uncontrolled asthma despite use of inhaled corticosteroids plus a long-acting beta-agonist (ICS/LABA): Final data
Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment
Year: 2015
Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results
Source: Eur Respir J 2012; 40: 17-27
Year: 2012
Placebo-controlled, double-blind trial of chronic, intermittent ‘pulse‘ therapy of moxifloxacin to prevent acute exacerbations in COPD patients with chronic bronchitis: baseline data
Source: Annual Congress 2006 - Clinical aspects and treatment of lower respiratory infection in COPD patients
Year: 2006
Long-term treatment with low-dose azithromycin reduces cough, sputum production and exacerbations in patients with idiopathic diffuse bronchiectasis
Source: Eur Respir J 2004; 24: Suppl. 48, 707s
Year: 2004
Patient-reported clinical control and peak-flow: Effects of 30 versus 6 month treatment with inhaled corticosteroids (ICS) with/without long-acting
2
-agonists (LABA) in moderately severe COPD
Source: Annual Congress 2011 - Disease management in specific primary care populations
Year: 2011
Efficacy, safety and tolerability of 3 day azithromycin (A)
versus
10-day conventional treatment (CT) in the treatment of children with acute asthma exacerbation (AE)
Source: Eur Respir J 2005; 26: Suppl. 49, 135s
Year: 2005
Effects and modulation of release rate of inhaled ciprofloxacin with liposomal formulations in healthy subjects and patients with bronchiectasis
Source: Annual Congress 2010 - New aspects of treatment of lower respiratory tract infections
Year: 2010
Baseline profiles of subjects randomised in RESPIRE 2 trial of ciprofloxacin dry powder for inhalation (DPI) in non-CF bronchiectasis (NCFB) by pathogen and prior exacerbation rate
Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations
Year: 2016
Comparative effectiveness of two different doses of inhaled corticosteroid in triple therapy on exacerbations in patients with severe COPD: a real-world study
Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19
Year: 2021
A randomised comparison of two tobramycin formulations in cystic fibrosis (CF) patients with chronic
pseudomonas aeruginosa
(PA) infection for pharmacokinetic and therapeutic equivalence
Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science
Year: 2013
Once-daily indacaterol/glycopyrronium (IND/GLY) reduces use of rescue medication versus twice-daily salmeterol/fluticasone (SFC) in patients with moderate-to-very severe COPD: results from the FLAME study
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
Efficacy of 12-month treatment with inhaled corticosteroid in bronchiectasis
Source: Eur Respir J 2003; 22: Suppl. 45, 514s
Year: 2003
Phase III trial of tiotropium as add-on therapy to low-dose inhaled corticosteroids for patients with symptomatic mild persistent asthma: Design and planned analyses
Source: Annual Congress 2013 –Asthma drugs: new findings
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept